Dana-Farber Cancer Institute
Project Term: October 1, 2022 - September 30, 2027
Despite decades of investigation and improved understanding of biology, patients with acute myelogenous leukemia (AML) who relapse after allogeneic hematopoietic cell transplantation face poor outcomes. We still do not have a complete understanding of the fundamental mechanisms of graft-versus-leukemia response or resistance. Our international team will explore the mechanisms by which the immune system evades AML and how discoveries made from interrogating patient samples and leveraging experimental models could lead to promising therapies to both prevent and treat recurrences. This proposal is highly collaborative and will comprehensively address mechanisms of immune evasion. This novel approach addresses key challenges in oncology and has the potential to bridge laboratory and clinical discovery through rapid translation to change the landscape of AML treatment.